
3-V Biosciences hires chief medical officer
pharmafile | November 26, 2013 | Appointment | Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing | 3V, biosciences, mcculloch
Clinical-stage biopharma firm 3-V Biosciences has taken on Dr William McCulloch as its chief medical officer.
McCulloch brings nearly three decades of senior R&D experience to 3-V, including an extensive pre-clinical and clinical development background in oncology.
At 3-V McCulloch will be responsible for its clinical, medical affairs and regulatory functions, and overseeing strategy and implementation for the advancement of the firm’s pipeline.
“With a thorough understanding of the oncology field and many years of relevant experience in the pharmaceutical and biotech industries, Bill brings significant breadth and depth to our executive team,” said Merdad Parsey, chief executive of 3-V.
McCulloch added: “I was attracted to this position based on the potential of TVB-2640, as well as 3-V’s wealth of opportunity based on its drug discovery capabilities, leadership team and backing from top venture capital firms.”
McCulloch previously served as chief medical officer at Gloucester Pharmaceuticals, where he led the regulatory strategy and oversaw the conduct of the pivotal trial that led to approval by the FDA for Istodax in 2009, and the subsequent acquisition of Gloucester by Celgene Corporation in later in 2010.
He also served as an executive VP and medical director at Pappas Ventures. McCulloch has worked for large pharma companies Bristol-Myers and Astra AB, start-up companies US Bioscience and Sparta Pharmaceuticals, and most recently has served as president of Alba BioPharm Advisors.
Related Content

BMS’ Opdivo wins US lung cancer race
The FDA has approved Bristol-Myers Squibb’s Opdivo (nivolumab) for the treatment of patients with metastatic …






